|
|
Influence of Different Embolic Materials on Tumor Volume and Postoperative Complications in Interventional Embolization of Giant Hepatic Hemangioma |
YE Cheng |
Zhoukou Central Hospital,Zhoukou Henan 466099 |
|
|
Abstract 【Objective】 To investigate the influence of different embolic materials on tumor volume and postoperative complications in interventional embolization of giant hepatic hemangioma. 【Methods】Clinical data of 94 patients with giant hepatic hemangioma admitted to our hospital from January 2020 to January 2022 were retrospectively analyzed. Patients were divided into the pingyangmycin group and the bleomycin group according to the embolic materials used during surgery, with 47 cases in each group. After 6 months of follow-up, clinical efficacy, blood supply typing, intraoperative lipiodol dosage, hospitalization status, and serum levels of alpha-fetoprotein (AFP), tumor-specific growth factor (TSGF), and tumor necrosis factor-α (TNF-α) were compared between the two groups. Postoperative complications were recorded. 【Results】There were no significant differences in blood supply typing, intraoperative lipiodol dosage, hospitalization time, or hospitalization costs between the two groups (P>0.05). The total effective rate of the pingyangmycin group was higher than that of the bleomycin group (P<0.05). At 3 and 6 months postoperatively, the tumor diameter in the pingyangmycin group was smaller, and the tumor shrinkage rate was higher than those in the bleomycin group (P<0.05). At 6 months postoperatively, serum levels of AFP, TSGF, and TNF-α in both groups were lower than those before surgery, and the levels in the pingyangmycin group were lower than those in the bleomycin group (P<0.05). There was no significant difference in the incidence of complications between the two groups (P>0.05). 【Conclusion】 The application of pingyangmycin-lipiodol mixture in interventional embolization of giant hepatic hemangioma is beneficial to improving clinical efficacy, with no serious complications and high safety.
|
Received: 20 May 2024
|
|
|
|
|
[1] 王晶,张洁,赵静.超声造影联合声触诊组织量化技术鉴别肝血管瘤与肝细胞癌价值研究[J].实用肝脏病杂志,2022,25(4):575-578.
[2] ÕZGÜR Ö, SINDEL H T. Giant hepatic hemangioma treatment with transcatheter arterial embolisation and transcatheter arterial chemoembolisation; Comparative results[J].Turk J Med Sci,2021,51(6):2943-2950.
[3] AYOOBI YAZDI N, MEHRABINEJAD M M, DASHTI H, et al. Percutaneous sclerotherapy with bleomycin and ethiodized oil: a promising treatment in symptomatic giant liver hemangioma[J].Radiology,2021,301(2):464-471.
[4] SHIN N, CHOI J A, CHOI J M, et al. Sclerotic changes of cavernous hemangioma in the cirrhotic liver: long-term follow-up using dynamic contrast-enhanced computed tomography[J].Radiol Med,2020,125(12):1225-1232.
[5] 国际肝胆胰协会中国分会肝血管瘤专业委员会.肝血管瘤诊断和治疗多学科专家共识(2019版) [J].中华消化外科杂志,2019,18(8):705-710.
[6] 黄笳,刘笑雷,谭海东,等.健康查体人群中肝血管瘤的流行病学及临床特点分析[J].中华医学杂志,2018,98(36):2925-2928.
[7] 张志成,袁广庆,莫灿均.肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析[J].实用肝脏病杂志,2019,22(5):736-739.
[8] 张薇聪,赵军凤,谭小蕖,等.超声引导下经皮穿刺注射平阳霉素硬化治疗肝血管瘤的有效性及安全性观察[J].中国医药,2024,19(2):236-239.
[9] 唐文涛,黄会,蔡婵娟.平阳霉素联合超化碘油混悬液经动脉介入栓塞治疗肝血管瘤患者中远期疗效研究[J].实用肝脏病杂志,2021,24(4):581-584.
[10] 牛传强,陈妙娟,申刚,等.博莱霉素碘油乳剂联合聚乙烯醇经导管动脉硬化栓塞治疗婴儿型肝血管内皮细胞瘤[J].中华放射学杂志,2017,51(3):206-209.
[11] WEI F, ZHONG R, PAN X, et al. Computed tomography-guided sub-end plate injection of pingyangmycin for a novel rabbit model of slowly progressive disc degeneration[J].Spine J,2019,19(2):6-18.
[12] HUANG Z, ZHANG N, CAI H, et al. Efficacy of propranolol and pingyangmycin, respectively, combined with pulsed dye laser on children with hemangioma[J].Exp Ther Med,2020,19(2):1197-1202.
[13] SHAN C K, DU Y B, ZHAI X T, et al. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation[J].Cancer Chemother Pharmacol,2021,87(3):425-436.
[14] 王宸,张雪斌,程乐.肝动脉介入栓塞术治疗肝血管瘤患者疗效及血清GPDA、GP73和β2-MG水平变化[J].实用肝脏病杂志,2020,23(6):905-908.
[15] GONZÁLEZ-NIETO M I, HOYOS L A E. A case of diffuse hepatic hemangiomatosis coexistent with giant hemangioma: case report and literature review[J].Radiol Case Rep,2021,16(6):1518-1523. |
|
|
|